Boston Scientific Corporation (NYSE: BSX) has announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood vessels in the peripheral vasculature. Latham & Watkins LLP represents Boston Scientific Corporation in the transaction with a corporate deal team led by Boston partner Julie Scallen, with Boston associates Stefanie Vincent, Michael Casagrande, Andrew Rondeau, and Nicole Angelica. Advice was also provided on tax matters by Washington, D.C. partner Nicholas DeNovio, with Washington, D.C. associates Pierce Pandolph and Emmanuel Kassim; on benefits and employment matters by Chicago partner Benjamin Rosemergy, with Chicago associate Daniel Gocek; and on healthcare regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang.~~